Finanzen von Lantern Pharma Inc (LTRN)LTRNLantern Pharma Inc

Evaluating the bottom line, Lantern Pharma Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -400.92%, provide a clear picture of how effectively LTRN converts its operational activities into shareholder value.

In the context of the broader market, LTRN competes directly with industry leaders such as TPST and AZR. With a market capitalization of $8.46M, it holds a significant position in the sector. When comparing efficiency, LTRN's gross margin of N/A stands against TPST's N/A and AZR's N/A. Such benchmarking helps identify whether Lantern Pharma Inc is trading at a premium or discount relative to its financial performance.

The company has not generated revenue in several quarters, with total revenue for Q1 2025 at only 100654.00 USD, and a net income loss of -7072124.00 USD in Q2 2026. The gross profit for Q1 2025 was -4574.00 USD, indicating ongoing financial challenges.